“…Somehow, taxanes have been found to be not cell specific with not all concentrations displaying similar effects on microtubules dynamics (Schiff et al, 1979;Schiff and Horwitz, 1980;Jordan et al, 1993;Derry et al, 1995;Jordan et al, 1996;Jordan and Wilson, 1998;Yvon et al, 1999) relating to unsimilar cytotoxic, anti-proliferative and apoptotic effects on various cancer cell lines namely breast, lung, ovary, prostate, hepatic, melanocyte and leukemic (Jordan et al, 1993;Jordan et al, 1996;Ferlini et al, 1998;Nehmé et al, 2001;Geng et al, 2003;Wang et al, 2005;Mahaffey et al, 2007;Mhaidat et al, 2007;Ichite et al, 2009;Kang et al, 2010). Though killing of malignant cells is the main aim for all researchers, scientists, cancer physicians and pharmaceutical companies; however, there are still many hedges and thorns to be overcome in order to attain a successful and irreproachable cancer therapy.…”